竞争的动态基因调节网络参与纤维细胞重编程到造血细胞的祖先细胞
Samiyah Shafiq1, Kiyofumi Hamashima2, Laura A Guest3
1Epigenetics of Haematopoiesis Laboratory, Division of Cancer Sciences, The University of Manchester, Manchester, UK; Cell Fate Engineering and Therapeutics Lab, Cell Biology and Therapies Division, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A(∗)STAR), Singapore, Republic of Singapore.
Stem cell reports
|April 4, 2025
概括
直接将体细胞重新编程为造血细胞是有希望的,但面临着挑战. 这项研究确定了关键的基因网络和途径,以提高治疗应用的重编程效率.
科学领域:
- 干细胞生物学 干细胞生物学
- 基因规则 基因规则
- 血液形成 血液形成 血液形成
背景情况:
- 将体细胞直接重新编程成患者特异性的造血细胞提供了一个更安全的治疗替代方案.
- 目前的策略受到随机性的限制,需要对潜在的基因调节网络进行调查.
研究的目的:
- 开发一种可诱导的系统,利用SCL和LMO2.2将纤维细胞重新编程为造血细胞的原始细胞.
- 调查基因调控网络,并确定提高重编程效率的目标.
主要方法:
- 开发了一种用于SCL和LMO2转录因子子子宫外表达的诱导系统.
- 在各种重编程阶段进行了转录组和表观组分析.
- 利用单细胞RNA测序来分析细胞命运决定.
主要成果:
- 实现了纤维细胞基因的均沉默,并提高了血源性内皮细胞程序的调节.
- 确定FLI1,GATA1/2和KLF14是SCL/LMO2的直接点,对于诱导造血程序至关重要.
- 在中间阶段发现了相互竞争的神经元命运决策,并证明抑制这些途径可以增强重编程.
结论:
- 确定了关键的早期和中间重编程事件和监管途径.
- 提供了针对特定途径的见解,以提高治疗目的直接细胞重编程的效率.
相关概念视频
Lineage Commitment
2.9K
Commitment is the process whereby stem cells:
2.9K
Methods of Nuclear Reprogramming
1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K
Somatic to iPS Cell Reprogramming
2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
Multipotency of Hematopoietic Stem Cells
3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Introduction to Fibroblasts
3.0K
Rudolph Virchow discovered spindle-shaped cells called fibroblasts in 1858. Inactive fibroblasts, called fibrocytes, become activated by various stimuli, such as growth factors and inflammatory cytokines. Activated fibroblasts play a crucial role in wound healing, inflammation, formation of new blood vessels, and cancer progression. Uncontrolled activation of fibroblasts results in fibrosis, the excess deposition of fibrous tissue, which can lead to scarring and affect normal organs. This...
3.0K


